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Hypoxia-mediated downregulation of miRNA
biogenesis promotes tumour progression
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Cancer-related deregulation of miRNA biogenesis has been suggested, but the underlying
mechanisms remain elusive. Here we report a previously unrecognized effect of hypoxia in
the downregulation of Drosha and Dicer in cancer cells that leads to dysregulation of miRNA
biogenesis and increased tumour progression. We show that hypoxia-mediated down-
regulation of Drosha is dependent on ETS1/ELK1 transcription factors. Moreover, mature
miRNA array and deep sequencing studies reveal altered miRNA maturation in cells
under hypoxic conditions. At a functional level, this phenomenon results in increased cancer
progression in vitro and in vivo, and data from patient samples are suggestive of miRNA
biogenesis downregulation in hypoxic tumours. Rescue of Drosha by siRNAs targeting
ETS1/ELK1 in vivo results in signiﬁcant tumour regression. These ﬁndings provide a new
link in the mechanistic understanding of global miRNA downregulation in the tumour
microenvironment.
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M
icroRNAs (miRNAs) are evolutionarily conserved small
RNA molecules intricately involved in gene regula-
tion1,2. Considering the broad functional involvement
of miRNAs in cellular homeostasis, it is not surprising that cancer
cells have altered miRNA levels2,3 and that miRNAs are
extensively involved in cancer progression4,5. Although global
miRNA downregulation in cancer has been reported2,6,7, the
mechanism of this downregulation is not fully understood.
Drosha and Dicer are key enzymes involved in miRNA
biogenesis. We and others have previously shown that down-
regulation of Drosha and Dicer in ovarian, lung and breast cancer
is associated with poor patient outcome7–11. Although individual
regulators of Dicer (for example, let7)12–16 have been implicated,
the underlying mechanisms are poorly deﬁned. In this study, we
identify new mechanisms of deregulation of miRNA biogenesis,
whereby hypoxia results in reduced Drosha and Dicer.
Speciﬁcally, we found that Drosha downregulation under
hypoxic conditions is mediated by ETS1/ELK1 and promoter
methylation. Moreover, Dicer is downregulated by epigenetic
mechanisms as deﬁned by van den Beucken et al.17 This study
uncovers precise mechanisms by which intra-tumoral hypoxia
suppresses miRNA expression by disrupting the miRNA
biogenesis machinery.
Results
Hypoxia downregulates miRNA biogenesis. First, we deter-
mined whether tumours have stable heterogeneity with regard to
Drosha and Dicer. We examined single-cell clones of A2780
ovarian cancer cells and found heterogeneous expression of
Drosha and Dicer (Supplementary Fig. 1a). To understand the
functional implications of this heterogeneity, we expanded and
injected two single-cell clones of A2780 cells into the peritoneal
cavity of mice (Clones 2 and 4). On analysis of individual tumour
samples, we observed that each sample had varying Drosha and
Dicer expression levels compared with the expression of clones at
the time of injection (Supplementary Fig. 1b).
This prompted us to consider whether changes in expression
levels of Drosha and Dicer could be dynamic and potentially
affected by the tumour microenvironment. Considering the
critical role of hypoxia in the tumour microenvironment18–20,
we tested levels of hypoxia in the clones with low Drosha and
Dicer, also A2780 tumour samples using the hypoxia marker
carbonic anhydrase 9 (CA9). In the cell clones, in vitro, we
observed variable levels of CA9 with small magnitude of changes
(Supplementary Fig. 1c). In contrast, the tumour samples with
low Drosha and Dicer levels displayed signiﬁcantly increased
expression of CA9, which was inversely correlated with Drosha
(Supplementary Fig. 1d) and Dicer (Supplementary Fig. 1e) levels.
We next tested the effect of hypoxia on Drosha and Dicer levels
using various cancer cell lines. In multiple cell lines exposed to
hypoxia, we observed marked reductions in Drosha and Dicer
messenger RNA and protein levels (Fig. 1a,b and Supplementary
Fig. 2a–e). This observed downregulation was consistent across
several time points (Supplementary Fig. 2e); the 48-h time point
was selected for all subsequent experiments. Drosha and Dicer
levels were signiﬁcantly increased after cells were restored to
normoxic conditions, demonstrating the dynamic nature of the
downregulation (Supplementary Fig. 2f). To test the possibility of
hypoxia-inducible factor-a (HIF1a) dependency in Drosha and
Dicer downregulation, we examined Drosha and Dicer expression
levels in mouse embryonic ﬁbroblasts with wild-type HIF1a or
HIF1a-knockout cultured under normoxic or hypoxic conditions.
HIF1a-knockout mouse embryonic ﬁbroblasts showed complete
abrogation in Drosha downregulation under hypoxia exposure and
partial abrogation in Dicer downregulation (Supplementary
Fig. 3a), suggesting that Drosha downregulation is highly
dependent on HIF1a. In addition, siHIF1a signiﬁcantly rescued
Drosha levels in hypoxia-exposed A2780 cells and Dicer levels
were partially rescued (Supplementary Fig. 3b). These data were
further supported by stabilization of HIFa by CoCl2 in A2780 cells
under normoxia. Increased CA9 was observed, followed by Drosha
and Dicer downregulation in CoCl2-treated samples compared
with control cells (Supplementary Fig. 3c). These data suggest a
HIF1a-dependent downregulation of Drosha. We observed Dicer
is downregulated in CoCl2-treated cells, but the mechanisms for
this effect are largely independent of HIF1a stabilization, as
reported by van den Beucken et al.17
In RNA samples isolated from microdissected hypoxic regions
of A2780 tumour samples, we observed signiﬁcantly increased
expression of hypoxia markers, CA9 and GLUT1. In the same
RNA samples, we observed 60% downregulation of Drosha and
Dicer (Fig. 1c,d). These data support our ﬁnding that hypoxia is
an important regulator of Drosha and Dicer downregulation in
cancer. As previous studies have shown that anti-vascular
endothelial growth factor (VEGF) therapies can increase
hypoxia21, we assessed Drosha and Dicer levels in mouse
tumour samples following treatment with bevacizumab. We
observed increased CA9 expression and, consequently,
signiﬁcantly decreased Drosha and Dicer expression levels in
tumours treated with bevacizumab compared with untreated
controls (Fig. 1e,f). To determine whether similar ﬁndings extend
to clinical samples, we analysed expression levels of Drosha, Dicer
and a hypoxia marker CA9 in human tumour samples (N¼ 30).
Results showed a signiﬁcant inverse correlation between CA9 and
Drosha and Dicer levels (Fig. 1g).
Effect of hypoxia on miRNA levels and clinical outcomes. We
next considered whether Drosha or Dicer downregulation leads to
impaired miRNA biogenesis by carrying out miRNA microarray
analysis of samples exposed to hypoxia or normoxia. On analysis
of mature miRNA array data, we observed signiﬁcant global
miRNA downregulation following exposure to hypoxia (Fig. 2a
and Supplementary data 1). Analysis of precursor and mature
miRNA levels from deep-sequencing data revealed signiﬁcant
downregulation of mature miRNAs, compared with their pre-
cursors (Fig. 2b and Supplementary data 2). Using quantitative
reverse transcriptase–PCR, we analysed the expression of seven
signiﬁcantly downregulated miRNAs from Fig. 2a, in cells
exposed to normoxia or hypoxia. There was a signiﬁcant increase
in pri-miRNA levels of six of seven miRNAs that were tested
(Fig. 2c). There was also signiﬁcant downregulation of corre-
sponding mature miRNA levels in response to hypoxia (Fig. 2d),
suggesting defective processing machinery under hypoxia con-
ditions. These data were further validated by northern blot ana-
lysis of miR-16a and 27a in cancer cells exposed to normoxia and
hypoxia (Supplementary Fig. 4a).
Next, to understand the individual contribution of Drosha and
Dicer downregulation in the miRNA processing downregulation,
we carried out quantiﬁcation of pri, precursor and mature
miRNAs in RNA from nuclear and cytoplasmic fractionated
A2780 cells exposed to normoxia or hypoxia. RNA from nuclear
fractionated samples had signiﬁcantly upregulated pri-miRNA
levels (Fig. 2e), consistent with the total RNA data in Fig. 2c.
Interestingly, we noted 440% reduction in precursor miRNA
levels in hypoxia-treated samples compared with normoxia
(Fig. 2f). In addition, samples from hypoxia-exposed cells had
460% reduction in mature miRNA levels compared with
normoxia in the cytoplasmic fraction (Fig. 2g).
Using the ovarian cancer data from the Cancer Genome Atlas
project (TCGA), we investigated the effect of low Drosha and
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Dicer levels on mature miRNA levels and observed that most
miRNAs (480%) were affected by downregulation of Drosha and
Dicer (Supplementary Fig. 4b). In the TCGA data set, we
observed signiﬁcantly worse median overall survival with low
Drosha and Dicer levels (Supplementary Fig. 4c). Using a hypoxia
metagene signature22, we examined the survival difference
between patients with high versus low hypoxia levels in their
tumours, according to the TCGA data. We observed signiﬁcantly
worse survival rates in patients whose tumours had high levels of
hypoxia (Supplementary Fig. 4d).
Drosha is downregulated by ETS family members. Next, we
investigated the mechanism by which hypoxia could regulate
Drosha expression. There was no signiﬁcant change in Drosha
mRNA half-life under hypoxic conditions (Supplementary
Fig. 5a), pointing to transcriptional regulation of Drosha. Inter-
estingly, we observed a small change in Dicer mRNA half-life
under hypoxia (Supplementary Fig. 5b). Luciferase activity for
the Drosha and Dicer promoters showed a signiﬁcant decrease in
Drosha promoter luciferase activity after exposure to hypoxia
in A2780 cancer cells (Fig. 3a and Supplementary Fig. 5c).
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Figure 1 | Hypoxia downregulates Drosha and Dicer in vitro and in vivo. (a) Drosha and Dicer mRNA expression levels under hypoxic conditions
(1% oxygen, 48 h) in A2780 cells. (b) Protein expression of Dicer, Drosha, hypoxia marker CA9, HIF1a and HIF2a under hypoxic conditions in A2780,
OVCAR3 and MCF7 cells. (c) Laser microdissection of hypoxic areas of tumours, guided by Hypoxyprobe staining (green). Scale bar, 500 mm. (d) mRNA
expression levels of hypoxia markers CA9 and GLUT1, as well as Dicer and Drosha expression levels, in normoxic and hypoxic regions of tumours
isolated using microdissection. (e) mRNA expression levels of CA9, Drosha and Dicer in A2780 mouse tumours treated with bevacizumab. (f) Protein
expression levels of Dicer (red), Drosha (red) and CA9 (green) in A2780 mouse tumour samples treated with bevacizumab compared with untreated
controls. Nucleus indicated in blue. Scale bar, 200mm. (g) Pearson correlation between Dicer and Drosha mRNA expression levels and hypoxia marker
CA9 levels (n¼ 30). All images shown are representative and data are presented as mean±s.e.m. of nZ3 experimental groups. *Po0.05, **Po0.01,
***Po0.001 (Student t-test).
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In addition, there was no signiﬁcant change in Drosha protein
half-life with hypoxia, suggesting that the mechanism is likely to
be transcriptional (Supplementary Fig. 5d).
To identify potential regulatory transcription factors, we
carried out bioinformatics analyses using Matinspector and
Matbase (Genomatix Inc.). In addition, we tested the role of
previously reported transcription factors in the hypoxia-mediated
downregulation of Drosha23–25. There was no signiﬁcant change
in Drosha following small interfering RNA (siRNA)-mediated
silencing of Myc, nuclear factor-kB or SP-1 transcription factors
(Supplementary Fig. 5e). From the bioinformatics analysis,
ETS1 and ELK1 were found to have binding sites on opposite
strands at very close proximity to the transcription initiation site
(Supplementary Fig. 5f), and a previous study demonstrated
transcriptional downregulation of downstream genes when
ETS1/ELK1 bind to regions with very close proximity to the
transcription initiation site26. Consistent with these ﬁndings, we
observed an increase in both mRNA and protein levels of ETS1
and ELK1 under hypoxic conditions (Fig. 3b and Supplementary
Fig. 5g,h). Of note, we also observed an increase in pELK1 levels,
suggesting that ELK1 is activated under hypoxic conditions
(Fig. 3b). In addition, we observed rescue of Drosha promoter
activity in cells with mutations at the ETS1 or ELK1 binding sites
under hypoxic conditions (Fig. 3c and Supplementary Fig. 5i).
Previous studies have demonstrated HIF1a-dependent increase in
ETS1 (ref. 27) and ELK1 via mitogen-activated protein kinase
signalling28 under hypoxia exposure. Nevertheless, we tested the
potential role of loss of miRNA repression under hypoxia
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exposure, resulting in increased ETS1 and ELK1. In
siDicerþ siDrosha-treated cells, we did not observe any
signiﬁcant change in ETS1 or ELK1 expression (Supplementary
Fig. 6). Moreover, we tested for CA9 and VEGF changes in
siDicerþ siDrosha-treated cells and observed no signiﬁcant
changes in their expression (Supplementary Fig. 6), ruling out
the possibility that miRNA repression loss as a mechanism for
CA9 or VEGF increase under hypoxia exposure. Next, we
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knocked down ETS1 and/or ELK1 to study the effect of these two
proteins on Drosha levels (Supplementary Fig. 7a,b). Drosha
expression was rescued after silencing ETS1, ELK1, or both,
suggesting that ETS1 and ELK1 serve as transcriptional repressors
for Drosha (Fig. 3d and Supplementary Fig. 7c). Chromatin
immunoprecipitation assays with anti-ETS1 and anti-ELK1 were
performed to conﬁrm deﬁnitive binding of these elements in the
promoter region. Compared with IgG or normoxic controls,
signiﬁcant enrichment in the binding of ETS1 and ELK1 to the
promoter region of Drosha was observed in A2780 (Fig. 3e and
Supplementary Fig. 8a) and MCF7 cells (Supplementary Fig. 8b)
under hypoxic conditions. In addition, we observed a signiﬁcant
reduction in polymerase II occupancy at the Drosha promoter
region under hypoxia conditions (Fig. 3e).
To elucidate potential mechanisms by which ETS family
members transcriptionally repress Drosha levels, we performed
Ingenuity Pathway Network analysis. This analysis revealed that
ETS1 could bind to the histone deacetylation-related molecule
HDAC1, and that ELK1 could bind to the DNA methylation-
related molecule ARID4B29,30 (Supplementary Fig. 9a).
A concentrated CpG island was observed near the Drosha
promoter region where ETS1 and ELK1 bind (Supplementary
Fig. 9b). Treatment of DNA samples with bisulphite and
methylation-speciﬁc PCR analysis revealed a signiﬁcant increase
in methylation at the ETS1 and ELK1 binding regions (Fig. 3f and
Supplementary Fig. 9c). Methylation-speciﬁc restriction enzyme
(MSRE) treatment and PCR analysis showed signiﬁcant
methylation at the CpG islands at the Drosha promoter region
following in vitro hypoxia exposure or in bevacizumab-treated
in vivo tumour samples (Supplementary Fig. 9d). In addition,
cells treated with siRNAs against ETS1 or ELK1 under hypoxia
showed signiﬁcant reversal of Drosha promoter methylation
compared with cells treated with control siRNA (Supplementary
Fig. 9e). Treatment of cells with the methylation inhibitor,
azacitidine, or the HDAC1 inhibitor, valproic acid, under hypoxic
conditions rescued Drosha levels, which was consistent with
methylation-speciﬁc PCR or MSRE data (Supplementary
Fig. 10a). In addition, in vivo tumour samples treated with
azacitidine showed signiﬁcant rescue of Drosha even under
hypoxic conditions induced by anti-VEGF therapy (VEGF-
targeted antibody, B-20), with a corresponding increase in ETS1
and ELK1 levels (Fig. 3g and Supplementary Fig. 10b). Cells
treated with the HIF1a antagonist topotecan31 under hypoxic
conditions showed rescue of Drosha by suppressing ETS1 across
several time points (Supplementary Fig. 10c,d), conﬁrming the
role of HIF1a-mediated signalling in ETS1 expression.
Importantly, immunoprecipitation of ETS1 and ELK1 from
hypoxia-treated cells showed clear binding of ARID4B and
HDAC1, respectively; this binding was abrogated by treatment of
cells with siETS1þ siELK1 under hypoxia (Fig. 3h and
Supplementary Fig. 11). Next, we performed Drosha chromatin
immunoprecipitation analysis using antibodies against ARID4B
and HDAC1. There was a signiﬁcant enrichment of ARID4B or
HDAC1 binding in the Drosha promoter region under hypoxia
exposure (Fig. 3i), conﬁrming the role of ETS1-ARID4B and
ELK1-HDAC1 complex in Drosha downregulation.
In the A2780 mouse model of ovarian cancer, using DOPC
(1,2-Dioleoyl-sn-glycero-3-phosphocholine) nanoliposomes to
deliver siRNAs against ETS1, ELK1, or both, we observed
signiﬁcant tumour reduction in the tumours treated with siETS1
and siELK1; the lowest tumour weight was observed in the
combination treatment group (Fig. 3j). Tumours from all three
treatment groups showed increased expression of Drosha
compared with the control group, and a signiﬁcant reduction in
ETS1 and ELK1 was observed in the treatment groups (Fig. 3k).
In the MCF7 orthotopic breast cancer model, treatment with the
combination of siETS1-DOPC and siELK1-DOPC resulted in
similar biological effects, suggesting that ETS1- and ELK1-
mediated Drosha deregulation is not limited to one particular
cancer type (Supplementary Fig. 12a–c). To understand the
clinical relevance to ETS1/ELK1 expression, we next examined
the correlation of ETS1 and ELK1 with patient survival by
analysing mRNA expression of ETS1 and ELK1 in human
tumour samples (n¼ 75). Patients with high tumoral ETS1 or
ELK1 expression had signiﬁcantly lower survival compared with
those with low ETS1 or ELK1 expression (Supplementary
Fig. 13a,b).
Functional effects of deregulated miRNA biogenesis. To iden-
tify potential tumour-promoting pathways affected by hypoxia,
we analysed mRNA expression data from deep sequencing cou-
pled with miRNA expression data from miRNA array analysis of
A2780 cells exposed to hypoxia and normoxia. Ingenuity Pathway
Network analysis of mRNA and miRNA data from deep
sequencing identiﬁed key novel miRNA–mRNA interactions that
could potentially lead to enhanced tumour progression under
hypoxic conditions (Supplementary Data 3 and 4). MiR-200, a
well-studied miRNA to play role in cancer growth and metastasis,
was one among the hypoxia-activated networks identiﬁed
(Supplementary data 4). Pathway enrichment analyses revealed
that cell adhesion, migration and growth networks were the most
signiﬁcantly upregulated pathways under hypoxic conditions
(Supplementary Fig. 14a). Cells under hypoxic conditions had
consistent upregulation of RHOB1, TAGLN, SERTAD1, TXNIP,
JAG1, CTGF and JUN, while corresponding miRNAs let7a, miR-
135a, miR-146a and miR-30c were signiﬁcantly downregulated
under hypoxic conditions (Figs 4a,b and 2d,g). Dicer and Drosha
silencing under normoxia resulted in similar downregulation of
the aforementioned miRNAs and corresponding upregulation of
genes (Fig. 4a,b). Ectopic expression of Dicer and Drosha under
hypoxia exposure resulted in rescue of the miRNAs and corre-
sponding downregulation of mRNA targets (Fig. 4a,b). In addi-
tion, we tested the known miR-185 and HIF2a axis15 in the
A2780 cancer cells following exposure to hypoxia. MiR-185 was
signiﬁcantly downregulated along with corresponding
upregulation of HIF2a (Supplementary Fig. 14b). In addition,
rescue of miR-185 by Drosha and Dicer ectopic expression or
delivery of miR-185 mimics under hypoxia exposure resulted in
signiﬁcant downregulation of HIF2a (Supplementary Fig. 14b).
These data further support the role of hypoxia-mediated Dicer
and Drosha deregulation in hypoxia signalling and tumour
progression.
Consistent with the altered pathways described above,
enhanced epithelial-to-mesenchymal transition (EMT) features
were observed in cells under hypoxic conditions (Supplementary
Fig. 15a). Analysis of EMT markers in various cell lines showed
signiﬁcantly decreased E-cadherin and increased vimentin mRNA
and protein levels under hypoxic conditions (Fig. 4c,d and
Supplementary Fig. 15b,c). RNA samples from the previously
discussed bevacizumab-treated A2780 tumours showed reduced
E-cadherin expression and increased vimentin expression,
consistent with our in vitro observations (Fig. 4e). To elucidate
the roles of Drosha and Dicer in the EMT process, we silenced
Drosha and Dicer in A2780 and MCF7 cells, after which we
observed signiﬁcantly decreased E-cadherin and increased
vimentin expression (Fig. 4f and Supplementary Fig. 16a). There
was signiﬁcant increase in migration and invasion of the A2780
or MCF7 cells after silencing of Dicer, Drosha, or both (Fig. 4g
and Supplementary Fig. 16b). Correlative analysis of E-cadherin
and CA9 in samples from patients with ovarian cancer showed a
signiﬁcant inverse correlation between E-cadherin and CA9
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expression (r¼  0.69, P¼ 0.0007). Vimentin expression, how-
ever, was positively correlated with CA9 expression (r¼  0.66,
P¼ 0.0013; Fig. 4h). We created stable cell lines ectopically
expressing Dicer and/or Drosha in HeyA8 ovarian cancer cells
that have low basal Drosha/Dicer expression levels, and exposed
the cells to hypoxia (Supplementary Fig. 17a–c). There was a
signiﬁcant reduction in EMT phenotype, including increased
E-cadherin and decreased vimentin expression in HeyA8-control
cells under hypoxia exposure. We observed disruption of
hypoxia-mediated induction of EMT phenotype on rescue of
Drosha and Dicer in these cells (Supplementary Fig. 17d). In
addition, a reduction in migration and invasion was observed in
all three cell line variants compared with control cells exposed to
hypoxia (Supplementary Fig. 17e,f). Next, we ectopically
expressed Drosha and Dicer in A2780 cells and tested
their effects after hypoxia exposure (Supplementary Fig. 17g).
There was signiﬁcant reduction in the EMT phenotype in
Drosha-, Dicer- or DroshaþDicer-expressing cells compared
with control cells exposed to hypoxia (Supplementary Fig. 17g).
Next, to understand the biological roles that Drosha and Dicer
play in tumour progression, we used an orthotopic model of
ovarian cancer with luciferase-labelled A2780 cells implanted in
the ovary. On knockdown of Drosha and Dicer using siRNAs
(DOPC), we observed signiﬁcant increases in aggregate tumour
weight (Fig. 5a), and number and incidence of distant metastatic
nodules (Fig. 5b) in the treatment groups compared with the
control group. These ﬁndings are consistent with the increase in
luciferase intensity observed in treatment groups (Fig. 5c). The
tumour metastasis rate was signiﬁcantly higher including rare sites
such as the liver in the siDicer-DOPC, siDrosha-DOPC and
combination treatment groups compared with the control group
(Fig. 5d and Supplementary Fig. 18a), which showed metastatic
lesions only in the mesentery. Reduction in Dicer or Drosha
expression in respective treatment groups was also observed
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(Fig. 5e). Decreased E-cadherin and increased vimentin protein
levels were observed in the siDicer, siDrosha and combination
treatment groups compared with the control group (Fig. 5f).
Similar increases in tumour weight and spread were observed with
Drosha and Dicer knockdown in intraperitoneal ovarian cancer
mouse models, resembling the clinical features of advanced-stage
disease (Supplementary Fig. 18b,c). Treatment with siDicerþ
siDrosha also produced a similar pattern in the MCF7 mouse
model of breast cancer with signiﬁcant increases in tumour growth
and metastatic rate being observed (Supplementary Fig. 19a–d). In
the HeyA8 in vivo model of ovarian cancer, ectopically expression
of Drosha, Dicer or DroshaþDicer resulted in signiﬁcant
reduction in tumour weight (Fig. 5g) and number of distant
metastatic nodules (Fig. 5h).
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We next sought to determine whether treatment with siETS1/
siELK1 could reverse the hypoxia-induced downregulation of
miRNA biogenesis machinery following treatment with bevaci-
zumab. Mice were treated with bevacizumab 2 weeks after
tumour establishment. There was a signiﬁcant increase in tumour
weight and number of metastatic nodules in the bevacizumab
treatment group (Fig. 6a). In mice treated with siETS1/siELK1, we
observed signiﬁcant reductions in tumour weight and number of
metastatic nodules and spread compared with mice treated with
bevacizumab alone (Fig. 6b,c). A signiﬁcant increase in CA9
expression was observed in mice that received anti-VEGF therapy
compared with control mice (Fig. 6d). Importantly, we noted
rescue of Drosha expression in the siETS/ELK1 treatment group
(Fig. 6e). Taken together, these data demonstrate the importance
of Drosha in tumour progression as well as the role of ETS1/ELK1
in its regulation.
Discussion
Our data show that tumour hypoxia plays a critical role in the
downregulation of Drosha and Dicer, leading to downregulated
miRNA biogenesis in cancer. Drosha is downregulated by ETS1
and ELK1 recruitment of HDAC1 and ARID4B onto the
promoter region. ETS1/ELK1 silencing under hypoxic conditions
in vivo rescued Drosha expression and led to signiﬁcant
reductions in tumour growth and metastasis (Fig. 7). During
progression, tumours encounter substantial hypoxia owing to
abnormal vasculature18. Emerging studies have shown that
hypoxia is involved in promoting tumour progression and
resistance to therapy18,19. Direct assessment of tumour
hypoxia in patient samples has demonstrated worse clinical
outcomes in patients with high intratumoral hypoxia20. In
addition, some studies suggest that anti-VEGF therapies induce
substantial hypoxia in tumours32,33. Previous reports have shown
hypoxia-mediated EMT via direct activation of Twist1 by
HIF1a (ref. 34) or notch signalling35. Our ﬁndings provide
a new understanding of the mechanisms by which hypoxia
contributes to increased cancer metastasis via miRNA biogenesis
downregulation.
Decreased expression of Drosha and Dicer in cancer is
associated with poor clinical outcome8–11. Recent reports
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Figure 7 | Schematic representation. Schematic representation of
mechanisms by which Drosha and Dicer downregulation in hypoxia results
in increased cancer growth and metastasis.
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showed the association of Dicer with increased metastasis using a
Dicer knockout36 or a breast cancer model37. Our study provides
further understanding of a previously unrecognized role of
hypoxia in the regulation of Drosha and Dicer. Use of Drosha-
and Dicer-independent siRNA-based gene targeting is an
emerging strategy to develop therapies that target undrugable
genes38–40. As suggested in this study, in vivo delivery of DOPC–
siETS1/ELK1 nanoparticles serve as a promising approach to
rescue expression of Drosha in cancer. Here we elucidated the
mechanism by which Drosha is downregulated under hypoxia
and provide new directions towards rescue of miRNA biogenesis
in cancer. Moreover, a parallel study by van den Beucken et al.17
describes a novel mechanism by which Dicer is downregulated
under hypoxia. Altogether, a comprehensive understanding of
Drosha and Dicer downregulation under hypoxic conditions is an
important leap towards understanding the miRNA biogenesis
defects that occur during cancer progression.
Methods
Cell line maintenance and siRNA and miRNA transfections. All cell lines were
maintained in 5% CO2 at 37 C. Ovarian cancer (A2780, OVCAR3, SKOV3,
OVCA432, HeyA8, IGROV, EG) and breast cancer (MDA-MB-231, MCF7,
GILM2) cells were obtained from the American Type Culture Collection and were
maintained in RPMI 1640 supplemented with 10–15% fetal bovine serum (FBS)
and 0.1% gentamicin sulfate (GeminiBioproducts, Calabasas, CA). All cell lines
were routinely tested to conﬁrm the absence of Mycoplasma, and all in vitro
experiments were conducted with 60–80% conﬂuent cultures.
All siRNA transfections (Supplementary Table 1) were performed using
RNAiMAX (Invitrogen, Carlsbad, CA) reagent using forward transfection protocol
from the manufacturer. Media was changed 5 h after transfections to minimize
toxicity. For all hypoxia treatments, cells were incubated in an oxygen-controlled
hypoxia chamber at 1% O2. For ectopic expression of Drosha and Dicer, we
obtained plasmids from Addgene (IDs 10828 and 25851, respectively). Next, we
cloned open reading frames into pLKO.1-GFP or Puromycin lentiviral plasmids.
We transduced HeyA8 cells with virus particles, and then selection using green
ﬂuorescent protein (Drosha) or puromycin (Dicer) was carried out to establish
stable cell variants.
In vivo models. Female athymic nude mice were purchased from Taconic Farms
(Hudson, NY). These animals were cared for according to guidelines set forth by
the American Association for Accreditation of Laboratory Animal Care and the US
Public Health Service policy on Human Care and Use of Laboratory Animals. All
mouse studies were approved and supervised by The University of Texas MD
Anderson Cancer Center Institutional Animal Care and Use Committee. All ani-
mals used were 8–12 weeks old at the time of injection.
Orthotopic models of ovarian cancer were developed as described
previously41,42. For all animal experiments, cells were harvested using trypsin-
EDTA, neutralized with FBS-containing media, washed and resuspended to the
appropriate cell number in Hanks’ balanced salt solution (HBSS; Gibco, Carlsbad,
CA) before injection. For the A2780 model, cells were injected either
intraperitoneally (1 106 cells in 200 ml of HBSS) or directly into the ovary
(0.8 106 cells in a 1:1 mixture of BD Matrigel and HBSS with a total volume of
100ml of HBSS). For the HeyA8 cells and variants expressing Drosha, Dicer and
DroshaþDicer (0.8 106 cells in a 1:1 mixture of BD Matrigel and HBSS with a
total volume of 100 ml of HBSS), intra-ovarian injections were performed. For the
breast cancer model, MCF7 cells were injected into the mammary fat pad (5 106
cells in a 1:1 mixture of BD Matrigel and HBSS). For the intra-ovary injections,
mice were anaesthetized with ketamine and xylazine. An incision just above the
approximate site of the right ovary was made to visualize the ovary. A 1-ml
tuberculin syringe with a 30-gauge needle was used to inject the cell suspension
directly into the ovary. After injection, the incision was closed using surgical clips
and the mouse was returned to a cage until fully recovered. For the orthotopic
breast cancer model, the MCF7 cell mixture was injected into the second mammary
fat pad from the top after the mouse was anaesthetized with ketamine and xylazine.
One week before the injection of breast cancer cells, a 60-day release pellet
containing 0.72mg of 17b-estradiol (Innovative Research of America, Toledo, OH)
was implanted subcutaneously into each mouse.
For all therapeutic experiments, a dose of 200 mg siRNA/kg was used, as
described previously39,42,43. For all models, unless indicated otherwise, twice
weekly treatments were started 1 week after cell injection and continued for
approximately 4 weeks. For miRNA or siRNA experiments, mice were randomly
divided and treated with siRNA incorporated in neutral DOPC nanoliposomes
(intraperitoneal administration). For the anti-VEGF therapy experiment, mice
were allowed to develop tumours for 2–3 weeks and then two treatments of
bevacizumab (6.25mg kg 1) were administered. For the Drosha and Dicer rescue
experiment, treatment with bevacizumab started on day 7 after cell implantation
and continued until the end of the experiment. In all experiments, once mice in any
group became moribund they were killed and necropsied, and tumours were
harvested. Tumour weight and number and location of tumour nodules were
recorded. Tumour tissue was either ﬁxed in formalin for parafﬁn embedded, frozen
in optimal cutting temperature media to prepare frozen slides, or snap-frozen for
lysate preparation.
Tumour samples. Tumour samples were obtained after the study was approved8
by the Institutional Review Board, and written informed consent was obtained
from the patients for the use of clinical specimens for research. We obtained 75
specimens of invasive epithelial ovarian cancer from the MD Anderson Cancer
Center Tumor Bank. For use as control samples, 15 normal ovarian epithelial
samples were also obtained. Frozen tumour samples (B0.2mg each) were used for
total RNA isolation using Trizol method.
TCGA data and bioinformatics analysis. Bioinformatics analysis was performed
in R (version 2.14.2; http://www.r-project.org). Statistical signiﬁcance was set at
Po0.05. We downloaded and analysed publicly available data from the TCGA
(http://tcga-data.nci.nih.gov/) for patients with high-grade serous ovarian carci-
noma. Level 3 Illumina RNASeq and miRNASeq were used to measure mRNA and
miRNA expression. miRNASeq data were derived from the ‘isoform_quantiﬁca-
tion’ ﬁles from the ‘reads per million miRNA mapped’ values for mature forms of
each microRNA. A list of 99 genes that comprised the hypoxia metagene was
obtained from Winter et al.22 Univariate Cox analysis was performed and ten genes
with hazard ratio 41.1 (KCTD11, TNS4, TUBB2A, ANGPTL4, TEAD4, DPM2,
PYGL, TPI1, C16orf74 and ADORA2B) were selected for further study. The median
of the distribution was calculated for each patient.
For survival analysis, the patients were grouped into percentiles according to the
hypoxia metagene signature described above. We checked for an association between
hypoxia signature and overall survival by choosing a cutoff to optimally split the
samples into two groups and the log-rank test was employed to determine the
signiﬁcance of the association. To examine the association between Drosha and Dicer
levels and overall survival, the patients were grouped into sextiles according to DICER
and DROSHA expression. We compared all groups and obtained the best separation
(minimal log-rank test P-value) for the groups linked to a positive association: DICER
expression last sextile and DROSHA expression last sextile with DICER expression
ﬁrst sextile and DROSHA expression ﬁrst sextile. We also compared miRNA levels
between two additional groups: good responders and bad responders.
Liposomal nanoparticle preparation. miRNA or siRNA for in vivo intratumour
delivery was incorporated into DOPC, as previously described43. DOPC and siRNA
were mixed in the presence of excess tertiary butanol at a ratio of 1:10 (w/w)
siRNA:DOPC. Tween 20 was added to the mixture in a ratio of 1:19 Tween
20:siRNA/DOPC. The mixture was vortexed, frozen in an acetone/dry ice bath and
lyophilized. Before in vivo administration, this preparation was hydrated with PBS
at room temperature at a concentration of 200mg siRNA per kg per injection.
miRNA microarray and deep sequencing. Total RNA was extracted from the
A2780 cells under normoxic or hypoxic conditions using the mirVana RNA Iso-
lation kit (Ambion). RNA purity was assessed using Nanodrop spectrophotometric
measurement (Thermo Scientiﬁc, Pittsburgh, PA) of the OD260/280 ratio with
acceptable values falling between 1.9 and 2.1, as well as using Agilent Bioanalyser
(Agilent Technologies, La Jolla, CA) with a RNA Integrity Number (RIN) number
of at least 8. Five hundred nanograms of total RNA was used for labelling and
hybridization, according to the manufacturer’s protocols (Agilent Technologies).
Expression levels of miRNAs in ovarian cancer cells on exposure to hypoxia (1%
O2) were proﬁled using miRNA microarray (Agilent v14). Bioinformatic analysis
was performed in R (version 2.14.2). Statistical signiﬁcance was set at Po0.05. The
raw intensity for each probe was the median feature pixel intensity with the median
background subtracted, and setting an offset 1 ensured that no negative values
would appear after log-transforming the data. Data were quantile-normalized and
log2 transformed. A two-sided t-test was applied to determine signiﬁcantly dif-
ferent miRNAs between samples. Heat maps were generated using the heat plot
function of the library.
Starting with 3 mg of total RNA for each sample, ribosomal RNA was depleted
using Ribominus (Invitrogen/Life Technologies, Inc., Carlsbad, CA), following the
manufacturer’s recommendations. Sequencing libraries were then prepared and
barcoded individually using the SOLiD Total RNA-Seq Kit for Whole
Transcriptome Libraries (Life Technologies), following the manufacturer’s
recommendations. Prepared samples were then pooled and sequenced using the
Life Technology 5500xl sequencer using 75 base forward read only. Data were
extracted from XSQ ﬁles containing the read sequences, quality values were loaded
onto a compute cluster and the reads were mapped in colorspace using the Life
Technologies LifeScope 2.5.1 software, using default parameters.
Reads were mapped to the human genome (hg19) downloaded from the UCSC
Genome Bioinformatics Site (http://genome.ucsc.edu). The hg19 genome was
slightly modiﬁed by deleting the Y chromosome to make a female genome. An
hg19 exon reference ﬁle provided by Life Technologies was required by LifeScope
to create the exon junction libraries needed to map reads that cross exon
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boundaries. This ﬁle was derived from the refGene database from UCSC. A human
ﬁlter reference ﬁle was required (provided by Life Technologies) that contains the
sequences of ribosomal and repetitive regions of the genome to ﬁlter reads that
mapped to those regions.
Mapped reads were output in the standard BAM (Binary Alignment/Map)
format. BAM ﬁles were imported into Partek Genomics Suite 6.6 (Partek
Incorporated, St Louis, MO) for gene expression analysis. Mapped reads contained
in the BAM ﬁles were cross-referenced against the RefSeq database (downloaded
from UCSC Genome Browser) and a small RNA database (UCSC Genome
Browser) to generate RPKM (reads per kilobase of exon per million mapped reads)
values for each gene. Low-expressing genes were excluded.
Differential expression using the derived RPKM values was performed using
analysis of variance. Genes with a false discovery rate o5% were considered
signiﬁcant. Signiﬁcantly deregulated miRNAs from the miRNA array and mRNA
data from deep sequencing were uploaded onto Ingenuity Pathway Network
analysis (Ingenuity Systems, www.ingenuity.com) and a network analysis with
miRNA–mRNA target analysis was carried out to identify potential gene
deregulation as a result of miRNA changes under hypoxic conditions.
Immunoblotting. Lysates from cultured cells were prepared using modiﬁed RIPA
buffer (50mM Tris–HCl (pH 7.4), 150mM NaCl, 1% Triton, 0.5% deoxycholate)
plus 25 mgml 1 leupeptin, 10mgml 1 aprotinin, 2mM EDTA and 1mM sodium
orthovandate. The protein concentrations were determined using a BCA Protein
Assay Reagent kit (Pierce Biotechnology, Rockford, IL). Lysates were loaded and
separated on SDS–PAGE. Proteins were transferred to a nitrocellulose membrane
by semidry electrophoresis (Bio-Rad Laboratories, Hercules, CA) overnight,
blocked with 5% BSA for 1 h and then incubated at 4 C overnight with primary
antibody (Dicer 1:1,000, Drosha 1:1,000 (Novus Biologicals, Littleton, CO), ETS1
1:500, ELK1 1:1,000, pELK1 1:500 (Cell signaling, Danvers, MA)). After washing
with tris-buffered saline with Tween 20, the membranes were incubated with
horseradish peroxidase-conjugated horse anti-Mouse or Rabbit IgG (1:2,000, GE
Healthcare, UK) for 2 h. Horseradish peroxidase was visualized using an enhanced
chemiluminescence detection kit (Pierce Biotechnology). To conﬁrm equal sample
loading, the blots were probed with an antibody speciﬁc for b-actin (0.1 mgml 1;
Sigma).
Immunoprecipitation using antibodies against ETS1 or ELK1 was carried out
using the Universal Magnetic Co-IP Kit (Active Motif, Carlsbad, CA), according to
instructions provided by the company. Samples were processed for western blotting
as described above. Using the antibody against ARID4B (Novus Biologicals) and
HDAC1 (Cell Signaling), pull-down samples were probed for interactions. Full
blottings are shown in Supplementary Figs 20 and 21.
Quantitative real-time PCR. For mRNA quantiﬁcation, total RNA was
isolated using the Qiagen RNeasy kit (Qiagen, CA). Using 1,000 ng of RNA,
complementary DNA was synthesized using a Verso cDNA kit (Thermo Scientiﬁc,
PA), as per the manufacturer’s instructions. Analysis of mRNA levels was
performed on a 7500 Fast Real-Time PCR System (Applied Biosystems, CA) with
SYBR Green-based real-time PCR for all genes, except the one speciﬁed. Dicer
and Drosha Taqman assays (Life Technologies) were performed. Speciﬁc
primers used are described in Supplementary Table 1. Semi-quantitative real-time
PCR was done with reverse-transcribed RNA and 100 ngml 1 sense and antisense
primers in a total volume of 20ml. For miRNA quantiﬁcation, total RNA was
isolated using Trizol (Invitrogen) extraction. RNA was isolated from nuclear
and cytoplasmic fractionated cells using Paris kit (Life Technologies). Fractionation
purity was conﬁrmed by running the samples on agarose gel electrophoresis
and visualization of precursor rRNA bands, 18 s, and 28 s rRNA bands. For
pri-miRNA and mature miRNA quantiﬁcations, taqMan miRNA assays (Life
Technologies) were used and reverse transcription, real-time PCR were carried
out, according to the manufacturer’s instructions. Precursor miRNAs were
quantiﬁed using c miRscript precursor miRNA assays (Qiagen). RNU6B
(for mature miRNAs) or 18S (pri and precursor miRNAs) were used as a
housekeeping gene.
Immunostaining. Staining was performed on optimal cutting temperature-
embedded frozen tissue sections. Protein blocking of nonspeciﬁc epitopes was
performed using 4% ﬁsh gelatin in tris-buffered saline with Tween 20 for 20min.
Slides were incubated with the primary antibody for Dicer, Drosha (Novus Bio-
logicals, CA), E-cadherin (BD Transduction Laboratories, CA) or vimentin (Cell
Signaling, CA) overnight at 4 C. For immunoﬂuorescence, secondary antibody
staining was performed using either Alexa 594 or Alexa 488 (Molecular Probes).
Nuclear staining was performed using Hoechst 33342 (Molecular Probes).
Immunoﬂuorescent images were captured using a Zeiss Axioplan 2 microscope and
Hamamatsu ORCA-ER digital camera (Carl Zeiss Inc., Germany) Bright-ﬁeld light
images of haematoxylin and eosin-stained lung tissue sections were obtained using
a Nikon Microphot-FXA microscope and Leica DFC320 digital camera (Nikon,
Japan; Leica, Germany). From each group, ten images were taken at random and
analysed for micrometastases, as well as scored for percentage of micrometastatic
nodules.
Migration and invasion assays. Modiﬁed Boyden chambers (Coster, MA) coated
with 0.1% gelatin (migration) or extracellular matrix components44 (invasion) were
used. A2780 or MCF7 cells (1 105) suspended in 100ml of serum-free media were
added into the upper chamber 24 h after siRNA transfections. Complete media for
cells containing 10% FBS (500 ml) was added to the bottom chamber as a chemo-
attractant. The chambers were incubated at 37 C in 5% CO2 for 6 h (migration) or
overnight (invasion). After incubation, the cells in the upper chamber were
removed with cotton swabs. Cells were ﬁxed and stained, and counted using light
microscopy. Cells from ﬁve random ﬁelds were counted. Experiments were done in
duplicate and performed three times.
MSP and MSRE analysis. For MSP, MethPrimer (http://www.urogene.org/
methprimer/) software was used for the prediction of the CpG island of the Drosha
promoter region and for design of methylation-speciﬁc primers (Supplementary
Table 1). Total DNA was isolated from normoxia- and hypoxia-treated cells using
Phenol:Chloroform extraction and then treated with bisulﬁte using a methylation
kit (EZ DNA Methylation-Gold; Zymo Research, CA). Using real-time PCR, as
described above, quantiﬁcation of methylation in hypoxia samples was performed
by comparing them with normoxia samples. For MSRE analysis, primers were
designed ﬂanking the CpG island predicted by MethPrimer with at least two CpG
islands on primers as suggested by qMethyl Light (Zymo Research). DNA samples
from hypoxia- and normoxia-exposed cancer cells were subjected to MSREs pro-
vided in the kit. Following MSRE digestion of DNA, quantiﬁcation of methylation
was carried out using real-time PCR. Percentage methylation was calculated by
comparing Ct values obtained from test (with MSRE) and reference (no MSRE)
reactions as outlined in the kit manual.
Northern blot analysis. RNA from cells treated with normoxia and hypoxia were
subjected to northern blot analysis using non-radioactive biotin-probe method45.
Brieﬂy, total RNA from A2780 cells exposed to normoxia and hypoxia was loaded
onto 15% urea gel, electrophoresed and transferred to nylon membranes at 10–
15V (90min) using Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad, CA). RNA
was cross-linked to the membrane using ultraviolet cross-linker. For miRNA and
U6 probes, pre-synthesized locked nucleic acid (LNA)-modiﬁed oligonucleotides
were purchased from Exiqon (http://www.exiqon.com) with biotin conjugation.
Hybridization and washing of the membranes were carried out using Northern
max kit (Life Technologies) according to the manufacturer’s recommended
protocol. Membranes were developed using Chemiluminescent Nucleic Acid
Detection Module (Pierce Biotechnology).
Actinomycin D mRNA stability assay. Drosha or Dicer mRNA stability under
hypoxic and normoxic conditions was assessed using 5 mgml 1 (ref. 46)
actinomycin D. Cells were grown in hypoxic or normoxic conditions for various
time periods with or without actinomycin D. At speciﬁed time points, RNA was
isolated and RNA levels of Drosha and Dicer were measured using real-time PCR,
as described above. 18S was used to normalize between the hypoxia and normoxia
samples. To assess RNA decay rates, Drosha and Dicer levels under hypoxic
conditions after normalization with 18S were compared with Drosha and Dicer
levels under normoxic conditions.
Chromatin hybridization and immunoprecipitation assay. Cells were cultured in
hypoxic or normoxic conditions for 48 h and chromatin immunoprecipitation
assays were performed using the Chip-it express kit (Active Motif), as described by
the manufacturer. In brief, cross-linked cells were collected, lysed, sonicated and
subjected to immunoprecipitation with the ETS1, ELK1, ARID4B and HDAC1
antibodies or IgG isotype control. Immunocomplexes were collected with protein
A/G agarose magnetic beads and eluted. Cross-links were reversed by incubating at
65 C with high salt concentration. PCR-based quantiﬁcation of fold enrichment in
ETS1 or ELK1 binding on the Drosha promoter region (primers used are in
Supplementary Table 1) was performed. The 2,500–3,000 base upstream region of
the ETS1 or ELK1 binding region was used as a control.
Microdissection and RNA isolation. In vivo tumour samples from a previous
study47 injected with Hypoxyprobe (Hypoxyprobe Inc., Burlington, MA) were used
for the present study. Frozen sections (10 mm) were afﬁxed onto polyethylene
terephthalate slides (Leica), ﬁxed in cold acetone (10min), washed in PBS three
times, stained for Hypoxyprobe using ﬂuorescein isithiocyanate-conjugated
antibody for 1 h on top of ice, washed and air-dried, and immediately followed
by dissection. Microdissection was performed using an MD LMD laser
microdissecting microscope (Leica). RNA was isolated from same samples using
the Cells to Ct Kit (Applied Biosystems), according to manufacturer instructions.
Real-time PCR was carried out to quantify gene expression.
Transcription factor binding analysis and luciferase assays. The promoter
region of Drosha was analysed for potential transcription factor binding using
Matinspector (Genomatix Inc., Germany), followed by analysis for a potential gene
suppression role using LitInspector (Genomatix). The Drosha promoter luciferase
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reporter assay was performed in A2780 and MCF7 cells using the Dual Luciferase
system (SwitchGear Genomics). Cells were transfected using FuGENE HD TFX
reagent in a 96-well plate with empty promoter or Drosha promoter (Switchgear
Genomics), along with the Cypridina TK control construct (pTK-Cluc). Cells were
treated with hypoxia or normoxia for 48 h and luciferase activity was measured
using the kit as described above. Mutation in the ETS1 or ELK1 binding region in
the Drosha promoter was created using the Quick change site-directed mutagenesis
kit (Agilent Technologies) and veriﬁed by sequencing. Primers used for muta-
genesis are listed in Supplementary Table 1.
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